These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26922537)

  • 1. Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases.
    Pytel E; Jackowska P; Chwatko G; Olszewska-Banaszczyk M; Koter-Michalak M; Kubalczyk P; Broncel M
    Pharmacol Rep; 2016 Apr; 68(2):344-8. PubMed ID: 26922537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease.
    Olszewska-Banaszczyk M; Jackowska P; Gorzelak-Pabiś P; Pytel E; Koter-Michalak M; Broncel M
    Pharmacol Rep; 2018 Apr; 70(2):258-262. PubMed ID: 29475008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Combined Ezetimibe/Atorvastatin Therapy vs. Atorvastatin Monotherapy on the Erythrocyte Membrane Structure in Patients with Coronary Artery Disease: A Pilot Study.
    Jackowska P; Pytel E; Koter-Michalak M; Olszewska-Banaszczyk M; Legęza A; Broncel M
    Adv Clin Exp Med; 2016; 25(3):433-9. PubMed ID: 27629730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease.
    Pytel E; Bukowska B; Koter-Michalak M; Olszewska-Banaszczyk M; Gorzelak-Pabiś P; Broncel M
    Pharmacol Rep; 2017 Feb; 69(1):150-155. PubMed ID: 27923158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Different Statin-Based Lipid-Lowering Strategies on C-Reactive Protein Levels in Patients With Stable Coronary Artery Disease.
    Xue Z; Ye M; Jiang H; Li D; Hong X; Chen Z; Li Y; Zhou B; Zhang W; Wang M
    Clin Cardiol; 2024 Jun; 47(6):e24301. PubMed ID: 38895772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
    Okada K; Kimura K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S
    Circ J; 2011; 75(10):2496-504. PubMed ID: 21817821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
    Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
    Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia.
    Sakuma M; Toyoda S; Hashimoto R; Yazawa H; Masuyama T; Hirose S; Waku R; Hasumi H; Numao T; Abe S; Inoue T
    Hypertens Res; 2019 Dec; 42(12):1923-1931. PubMed ID: 31409915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
    Hiro T; Hirayama A; Ueda Y; Komatsu S; Matsuoka H; Takayama T; Ishihara M; Hayashi T; Saito S; Kodama K;
    J Cardiol; 2014 Dec; 64(6):501-7. PubMed ID: 24725763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease.
    Jin J; Shan L; Wang M; Liu L; Xu T; Li D; Chen Z; Liu X; Zhang W; Li Y
    Int Heart J; 2023 Sep; 64(5):807-815. PubMed ID: 37704407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of statin monotherapy and statin-ezetimibe combined therapy on FoxP3 and IL 10 mRNA expression in patients with coronary artery disease.
    Jackowska P; Chałubiński M; Łuczak E; Wojdan K; Gorzelak-Pabis P; Olszewska-Banaszczyk M; Broncel M
    Adv Clin Exp Med; 2019 Sep; 28(9):1243-1248. PubMed ID: 31430072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
    Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
    Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M
    Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin.
    Ran D; Nie HJ; Gao YL; Deng SB; Du JL; Liu YJ; Jing XD; She Q
    Int J Cardiol; 2017 May; 235():49-55. PubMed ID: 28291622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Ono T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Cardiol; 2015 Oct; 66(4):353-8. PubMed ID: 25577723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.